217 related articles for article (PubMed ID: 24120483)
1. Sustained functional serotype-specific antibody after primary and secondary vaccinations with a pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease.
Ohshima N; Nagai H; Matsui H; Akashi S; Makino T; Akeda Y; Oishi K
Vaccine; 2014 Feb; 32(10):1181-6. PubMed ID: 24120483
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety after the third vaccination with the 23-valent pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease.
Ohshima N; Akeda Y; Nagai H; Oishi K
Hum Vaccin Immunother; 2020 Sep; 16(9):2285-2291. PubMed ID: 32048894
[TBL] [Abstract][Full Text] [Related]
3. Hyporesponsiveness to the infecting serotype after vaccination of children with seven-valent pneumococcal conjugate vaccine following invasive pneumococcal disease.
Tamura K; Matsubara K; Ishiwada N; Nishi J; Ohnishi H; Suga S; Ihara T; Chang B; Akeda Y; Oishi K;
Vaccine; 2014 Mar; 32(13):1444-50. PubMed ID: 24486367
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the immunogenicity and safety of polysaccharide and protein-conjugated pneumococcal vaccines among the elderly aged 80 years or older in Japan: an open-labeled randomized study.
Namkoong H; Funatsu Y; Oishi K; Akeda Y; Hiraoka R; Takeshita K; Asami T; Yagi K; Kimizuka Y; Ishii M; Tasaka S; Suzuki Y; Iwata S; Betsuyaku T; Hasegawa N
Vaccine; 2015 Jan; 33(2):327-32. PubMed ID: 25448102
[TBL] [Abstract][Full Text] [Related]
5. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults.
Musher DM; Manof SB; Liss C; McFetridge RD; Marchese RD; Bushnell B; Alvarez F; Painter C; Blum MD; Silber JL
J Infect Dis; 2010 Feb; 201(4):516-24. PubMed ID: 20092407
[TBL] [Abstract][Full Text] [Related]
6. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses.
Kawakami K; Kishino H; Kanazu S; Toshimizu N; Takahashi K; Sterling T; Wang M; Musey L
Vaccine; 2016 Jul; 34(33):3875-81. PubMed ID: 27265450
[TBL] [Abstract][Full Text] [Related]
7. Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine.
Millar EV; O'Brien KL; Bronsdon MA; Madore D; Hackell JG; Reid R; Santosham M
Clin Infect Dis; 2007 May; 44(9):1173-9. PubMed ID: 17407035
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
[TBL] [Abstract][Full Text] [Related]
9. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.
Thanee C; Pancharoen C; Likitnukul S; Luangwedchakarn V; Umrod P; Phasomsap C; Apornpong T; Chuanchareon T; Butterworth O; Puthanakit T
Vaccine; 2011 Aug; 29(35):5886-91. PubMed ID: 21729732
[TBL] [Abstract][Full Text] [Related]
10. Immunological responses to pneumococcal vaccine in frail older people.
Ridda I; Macintyre CR; Lindley R; Gao Z; Sullivan JS; Yuan FF; McIntyre PB
Vaccine; 2009 Mar; 27(10):1628-36. PubMed ID: 19100304
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.
Frenck RW; Fiquet A; Gurtman A; van Cleeff M; Davis M; Rubino J; Smith W; Sundaraiyer V; Sidhu M; Emini EA; Gruber WC; Scott DA; Schmoele-Thoma B;
Vaccine; 2016 Jun; 34(30):3454-62. PubMed ID: 27155493
[TBL] [Abstract][Full Text] [Related]
12. The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial.
Dagan R; Givon-Lavi N; Porat N; Greenberg D
Vaccine; 2012 Jul; 30(34):5132-40. PubMed ID: 22683519
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
14. Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B.
Saeland E; Jakobsen H; Ingolfsdottir G; Sigurdardottir ST; Jonsdottir I
J Infect Dis; 2001 Jan; 183(2):253-260. PubMed ID: 11110649
[TBL] [Abstract][Full Text] [Related]
15. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants.
Dagan R; Kayhty H; Wuorimaa T; Yaich M; Bailleux F; Zamir O; Eskola J
Pediatr Infect Dis J; 2004 Feb; 23(2):91-8. PubMed ID: 14872172
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
[TBL] [Abstract][Full Text] [Related]
17. Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly.
Kawakami K; Kishino H; Kanazu S; Takahashi K; Iino T; Sawata M; Musey L
Hum Vaccin Immunother; 2018; 14(8):1931-1938. PubMed ID: 29580133
[TBL] [Abstract][Full Text] [Related]
18. Functional immune responses to twelve serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults.
Ahn JG; Kim HW; Choi HJ; Lee JH; Kim KH
Vaccine; 2015 Sep; 33(38):4770-5. PubMed ID: 26277073
[TBL] [Abstract][Full Text] [Related]
19. Impaired serotype-specific immune function following pneumococcal vaccination in infants with prior carriage.
Licciardi PV; Russell FM; Balloch A; Burton RL; Nahm MH; Gilbert G; Tang ML; Mulholland EK
Vaccine; 2014 Apr; 32(20):2321-7. PubMed ID: 24613524
[TBL] [Abstract][Full Text] [Related]
20. Dependence of correlations between antibody titres and opsonophagocytosis on pneumococcal serotype and patient morbidity in pre- and post-pneumococcal vaccination states.
Tarragó D; Aguilar L; Jansen WT; Giménez MJ; Avellón A; Granizo JJ; Casal J
Clin Microbiol Infect; 2007 Apr; 13(4):369-76. PubMed ID: 17359320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
